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Abstract
Background: ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen
receptor-negative tumors. ADAM12 is induced during epithelial-to-mesenchymal transition, a feature associated
with claudin-low breast tumors, which are enriched in cancer stem cell (CSC) markers. It is currently unknown
whether ADAM12 plays an active role in promoting the CSC phenotype in breast cancer cells.
Methods: ADAM12 expression was downregulated in representative claudin-low breast cancer cell lines, SUM159PT
and Hs578T, using siRNA transfection or inducible shRNA expression. Cell characteristics commonly associated with
the CSC phenotype in vitro (cell migration, invasion, anoikis resistance, mammosphere formation, ALDH activity, and
expression of the CD44 and CD24 cell surface markers) and in vivo (tumor formation in mice using limiting dilution
transplantation assays) were evaluated. RNA sequencing was performed to identify global gene expression changes
after ADAM12 knockdown.
Results: We found that sorted SUM159PT cell populations with high ADAM12 levels had elevated expression of
CSC markers and an increased ability to form mammospheres. ADAM12 knockdown reduced cell migration and
invasion, decreased anoikis resistance, and compromised mammosphere formation. ADAM12 knockdown also
diminished ALDEFLUOR+ and CD44hi/CD24-/lo CSC-enriched populations in vitro and reduced tumorigenesis in mice
in vivo. RNA sequencing identified a significant overlap between ADAM12- and Epidermal Growth Factor Receptor
(EGFR)-regulated genes. Consequently, ADAM12 knockdown lowered the basal activation level of EGFR, and this
effect was abolished by batimastat, a metalloproteinase inhibitor. Furthermore, incubation of cells with exogenously
added EGF prevented the downregulation of CD44hi/CD24-/lo cell population by ADAM12 knockdown.
Conclusions: These results indicate that ADAM12 actively supports the CSC phenotype in claudin-low breast
cancer cells via modulation of the EGFR pathway.
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Background
Members of the ADAM family of cell surface metallo-
proteases catalyze cell context-dependent cleavage of
transmembrane receptors, growth factor precursors, or
adhesion molecules [1, 2]. ADAM substrates include
many cancer-related proteins, such as Notch receptors
and their ligands [3], epidermal growth factor receptor
(EGFR) ligands [4, 5], interleukin-6 receptor (IL-6R) [6],
tumor necrosis factor (TNF) and its receptors [7], E-
cadherin [8], and CD44 [9]. Because ADAMs are often
aberrantly expressed or misregulated in human cancers,
they may contribute to tumor progression, metastasis, or
therapy resistance [10–12].
Among twelve catalytically active human ADAMs [2],
ADAM12 possesses unique characteristics that make it
an attractive candidate for future use as a target or a bio-
marker in breast cancer. ADAM12 expression is strongly
elevated in most human breast cancers compared to
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normal mammary epithelium [13, 14]. ADAM12 mRNA
is alternatively spliced, and high levels of ADAM12 tran-
script variant 1 (encoding the transmembrane protein iso-
form ADAM12-L) are associated with poor prognosis and
decreased metastasis-free survival times in estrogen recep-
tor (ER)-negative, progesterone receptor (PR)-negative, and
human epidermal growth factor receptor 2 (HER2)-nega-
tive (triple-negative) early stage breast cancers without sys-
temic treatment, but not in HER2-positive or ER-positive
tumors [15, 16]. ADAM12-L expression is induced during
epithelial-to-mesenchymal transition (EMT) in mammary
epithelial cells [17] and appears to be upregulated in the
claudin-low intrinsic subtype of breast cancer [18], which
harbors molecular signatures of EMT. Claudin-low tumors
represent ~5-10% of all breast cancers, are often triple-
negative and poorly differentiated, and have elevated activ-
ities of EGFR, proto-oncogene tyrosine kinase Src, trans-
forming growth factor β (TGFβ), and signal transducer and
activator of transcription 3 (STAT3) pathways [19–21].
Importantly, the gene expression signatures of claudin-low
tumors show a significant similarity to the signature of
CD44hi/CD24-/lo mammosphere-forming cells [20, 22],
suggesting an enrichment in cancer stem cell (CSC)-like or
tumor-initiating cell features. Breast CSCs are thought to
be largely responsible for tumor maintenance, treatment
resistance, and disease recurrence [23–25]. Our previous
analysis of two clinical datasets showed that elevated
expression of ADAM12 mRNA is predictive of resistance
to neoadjuvant chemotherapy in ER-negative breast can-
cer, independent of age, tumor size, grade, and the lymph
node status [18]. These observations raise a possibility that
ADAM12 may serve as a marker or a therapeutic target in
CSCs in ER-negative or triple-negative breast cancer
(TNBC).
The goal of the current study was to assess a possible
contribution of ADAM12 to the CSC phenotype of
claudin-low TNBC cells. By comparing the properties of
sorted cell populations with high versus medium expres-
sion of ADAM12, and by analyzing the effect of ADAM12
knockdown on cell migration, invasion, anoikis resistance,
mammosphere formation, known CSC markers, tumor
formation after xenotransplantation in mice in vivo, and
global gene expression, we have determined that ADAM12
actively supports the CSC phenotype of claudin-low TNBC
cells. This function of ADAM12 appears to be mediated by
sustained, ligand-dependent activation of EGFR. Thus, we
have identified ADAM12 as an important modifier of the
EGFR pathway in claudin-low TNBC and a potential target
in CSC-directed therapies.
Methods
Reagents and antibodies
SMARTpool ADAM12 siRNA (M-005118-01, target se-
quences 5’-GCAAAGAACTGATCATAAA-3’, 5’-GATG
AGAGATGCTAAATGT-3’, 5’-GCAGCAAGGAGGCCG
GATT-3’, and 5’-GTCAGGATGTGGACGGCTA-3’),
ADAM12 siRNA#1 (D-005118-01, target sequence 5’-
GCAAAGAACTGATCATAAA-3’), ADAM12 siRNA#2
(D-005118-02, target sequence 5’-GATGAGAGATGC-
TAAATGT-3’), and DharmaFECT1 transfection reagent
were from GE Dharmacon. These siRNAs targeted
transcript variant 1 (NCBI Ref. Seq. NM_003474) and
transcript variant 2 (NCBI Ref. Seq. NM_021641) of
ADAM12, encoding ADAM12-L and ADAM12-S protein
isoforms, respectively. As a negative control, siGENOME
non-targeting siRNA pool (D-001206-13) or ON-
TARGETplus non-targeting siRNA pool (D-001810-10,
GE Dharmacon) was used. RT2 Profiler arrays were from
Qiagen, erlotinib was from Cell Signaling Technology,
batimastat was from EMD Millipore, bFGF, B27, and
human recombinant EGF were from Life Technologies.
Antibodies used for flow cytometry were: PE-conjugated
anti-CD24 (clone ML5) and IgG2aκ isotype control (clone
G155-178, both from BD Biosciences), APC-conjugated
anti-CD44 (clone IM7) and IgG2bκ isotype control (clone
eB149/10H5, both from Affymetrix eBioscience), anti-
ADAM12 (clone 632525) and IgG1 isotype control (clone
11711, both from R&D Systems). APC- or AlexaFluor488-
conjugated secondary anti-mouse IgG1 antibodies were
from Jackson ImmunoResearch. For Western blotting, the
following antibodies were used: rabbit monoclonal anti-
pY1068 EGFR (clone D7A5) and anti-total EGFR (clone
D38B1), both from Cell Signaling Technology, and rabbit
polyclonal anti-ADAM12 antibody (Ab#3394) raised
against the cytoplasmic tail of human ADAM12 [16].
Cell culture
SUM149PT, SUM159PT, and SUM1315MO2 cell lines
were purchased from Asterand, BT549, Hs578T, and
MCF-7 cells were from ATCC, and HEK293T cells were
from Thermo Scientific. SUM102PT and SUM225CWN
cells were gifts from Dr. Fariba Behbod (University of
Kansas Medical Center). All cell lines were authenticated
by the original suppliers using the short tandem repeat
(STR) analysis and have been passaged for fewer than
6 months after culture initiation from an early passage
number. Tumor source and pathological features of
tumors used to derive breast cancer cell lines used in
this study are summarized in Additional file 1: Table S1
[19, 26–29]. SUM149PT, SUM159PT, and SUM225CWN
cells were cultured in Ham’s F-12 medium supple-
mented with 5% fetal bovine serum (FBS), 10 mM
HEPES, 5 μg/ml insulin, and 1 μg/ml hydrocortisone.
SUM1315MO2 cells were cultured in Ham’s F-12
medium supplemented with 5% FBS, 10 mM HEPES,
10 ng/ml EGF, and 5 μg/ml insulin. SUM102PT cells
were maintained in Ham’s F-12 medium containing 5%
FBS, 1 μg/ml hydrocortisone, and 5 μg/ml insulin.
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BT549 cells were cultured in RMPI1640 medium supple-
mented with 10% FBS, 1 mM pyruvate, and 0.8 μg/ml
insulin. Hs578T and MCF-7 cells were cultured in
DMEM medium containing 10% FBS and 10 μg/ml
insulin. HEK293T cells were cultured in DMEM medium
containing 10% FBS, 6 mM glutamine, and 1 mM pyru-
vate. Cells were maintained at 37 °C under humidified
atmosphere containing 5% CO2.
Virus production and generation of stable cell lines
shRNA targeting human ADAM12 and control shRNA in-
serts were excised from GIPZ ADAM12 shRNA lentiviral
vector (V2LHS_11814; the mature antisense sequence: 5’-
TTGACATTGACGATTCAGG-3’) or non-silencing con-
trol shRNA construct (RHS4346; GE Dharmacon), respect-
ively, and were cloned into pInducer10 vector (Addgene,
plasmid 44011) at the XhoI and MluI sites. The ADAM12
shRNA construct targeted both transcript variant 1 and 2
of ADAM12. Lentiviruses were produced by transfecting
HEK293T cells with pInducer10-shADAM12/shControl,
pMD2.G, and psPAX2 (Addgene, plasmids 12259 and
12260, respectively) using Mirus TransIT transfection re-
agent (Mirus). Conditioned media containing viral particles
were harvested 48 h after transfection, supplemented with
5 μg/ml polybrene (Sigma), and added onto SUM159PT
cells at ~20% confluence. Selection of stably transduced
cells started 48 h after infection using 2 μg/ml puromycin
and continued for 10 days.
Flow cytometry
ALDEFLUOR assay: SUM159PT cells and Hs578T cells
were transfected with SMARTpool ADAM12 siRNAs or
non-targeting siRNAs. Three days after transfection, 106
cells were suspended in 1 ml ALDEFLUOR assay buffer
and 5 μl ALDEFLUOR reagent (STEMCELL) was added.
Then, 0.5 ml cells were immediately transferred to a new
tube containing 10 μl ALDH inhibitor diethylamino-
benzaldehyde (DEAB, negative control). Both DEAB-
treated and untreated cells were incubated at 37 °C for
45 min, centrifuged, resuspended, and analyzed by flow
cytometry. CD24 and CD44 staining: Three days after
transfection, cells were stained with PE-conjugated anti-
CD24 and APC-conjugated anti-CD44 antibodies, or their
respective isotype antibody controls, and analyzed by flow
cytometry. ADAM12 staining: Cells were incubated with
anti-ADAM12 antibody or mouse IgG1 isotype control
antibody, washed and incubated with APC-conjugated
anti-mouse IgG antibody. Cells were analyzed with a BD
FACSCalibur cytometer or a LSR Fortessa X20 instru-
ment. All data were analyzed with FCS Express 4 (DeNovo
Software). For cell sorting, single cell suspensions stained
with anti-ADAM12 antibody and with AlexaFluor488-
conjugated anti-mouse IgG antibody were sorted on
Bio-Rad S3 cell sorter into ADAM12hi population
(~1.5% of cells with the highest expression of ADAM12)
and ADAM12med population (medium expression of
ADAM12).
Transwell migration and matrigel invasion assays
SUM159PT shADAM12 and shControl cells were
treated with or without 1 μg/ml doxycycline for 4 days.
Transwell migration assay was then performed, as de-
scribed [30]. Migrated cells underneath the inserts were
analyzed by light microscopy using 10x magnification
and photographed. The numbers of migrated cells were
counted in five random fields for each insert. For inva-
sion assays, growth factor-reduced Matrigel (Corning,
200 μl at 6.3 mg/ml) was layered into wells of a 24-well
plate and allowed to solidify at 37 °C. Cells were pre-
treated for 4 days with or without 1 μg/ml doxycycline,
detached, and diluted to 2.5x104 cells/ml. Cells (10 μl)
were mixed with 190 μl diluted Matrigel, placed onto
the Matrigel base layer, and incubated at 37 °C. After the
cell layer solidified, 500 μl of complete growth medium
supplemented with 2 μg/ml doxycycline was placed on
top and incubated at 37 °C for 12 days. Cells were visu-
alized on a Nikon inverted microscope at 4x magnifica-
tion and photographed.
Sphere formation
Cells were treated without or with 1 μg/ml doxycycline
for 4 days, detached with 0.25% trypsin/5 mM EDTA in
DPBS, and diluted to 1x106 cells/ml. Single cell suspen-
sion was passaged through a cell strainer and then
diluted to 5x103 cells/ml with mammosphere medium
containing MEMB, 20 ng/ml hEGF, 20 ng/ml bFGF,
4 μg/ml heparin, 1xB27, and 1x Penicillin/Streptomycin.
Cells were mixed with 3% methylcellulose (R&D
Systems) at a 2:1 ratio and seeded into wells of 24-well
ultra-low attachment plates (Corning) at 1x103 cells/
well. After 7 days, six randomly selected areas from each
well were analyzed by inverted light microscopy using a
4x objective and photographed. Numbers of spheres in
each image were quantified using ImageJ.
Cell growth and cell death assays
ADAM12hi and ADAM12med sorted cells were seeded
into 96-well plates (100 cells/well) and incubated for
5 days in growth medium. Cell growth was measured
using CellTiter-Glo Luminescent Cell Viability Assay
(Promega); at least 5 wells per cell type were measured
for each time point. Growth rate and doubling times
were calculated using GraphPad Prism.
For cell death assays, 1x103 cells treated without or
with 1 μg/ml doxycycline for 4 days were suspended in
mammosphere medium containing 1% methylcellulose
and seeded into wells of a 24-well ultra-low attachment
plate. Cells were pelleted at 0, 12, 24, and 48 h post-
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plating, washed twice, lysed at 4 °C for 15 min, and
frozen at -20 °C. Cell Death ELISA kit (Roche) was used
to detect fragmented mono- and oligo-nucleosomes in
lysates preserved at different time points.
Immunoblotting
Immunoblotting was performed as described [16, 18],
with some modifications. Lysis buffer was supplemented
with phosphatase inhibitors (50 mM NaF, 2 mM
Na3VO4, and 10 mM Na4P2O7). Total cell lysates were
directly analyzed by Western blotting or incubated with
concanavalin A agarose (Sigma; 50 μl resin per 1 ml cell
lysate) for 2 h at 4 °C to enrich for glycoproteins. The
resin was washed three times and glycoproteins were
eluted with 3X SDS gel loading buffer. Nitrocellulose
membranes were incubated with primary monoclonal
antibodies and HRP-conjugated secondary antibodies,
followed by signal detection using SuperSignal West Pico
or West Femto chemiluminescence detection kit (Pierce)
and Azure c500 digital imaging system. Band intensities
were quantified using the ImageJ analysis software.
Quantitative real-time PCR
Total RNA was extracted using the Qiagen RNeasy kit
and was subjected to on-column digestion with deoxy-
ribonuclease I. One microgram of total RNA was
reverse-transcribed using the SuperScript III First Strand
Synthesis system (Invitrogen) or the qScript Flex cDNA
kit (Quanta BioSciences) and oligo(dT) primers. Quanti-
tative real time PCR (qRT-PCR) was performed on a
BioRad CFX96 instrument. At the conclusion of each
run, a melt curve analysis was performed to ensure that
a single product had been synthesized. The relative
expression of each gene, normalized to actin, was calcu-
lated using the 2-ΔΔCt method. Primer sequences are
provided in Additional file 1: Table S7.
Tumor formation in vivo
All animal experiments were performed in accordance
with protocols approved by the Institutional Animal
Care and Use Committee at Kansas State University.
Non-obese diabetic severe combined immunodeficient
(NOD-SCID) female mice were obtained from Charles
River Laboratories. One week prior to injection, mice
were randomized to either control or doxycycline diet
(2 g/kg, Bio-Serv) and they remained on this diet
throughout the experiment. shControl and shADAM12
SUM159PT cells were pre-treated for 4 days with or with-
out 1 μg/ml doxycycline. Cells were detached and serially
diluted in 1% BSA/DPBS; each dilution was combined
with an equal volume of ice-cold growth factor-reduced
Matrigel. Cells (100 μl) were injected subcutaneously in
the 4th inguinal mammary glands of 8-week old female
NOD-SCID mice under isoflurane sedation. Mice were
monitored for tumor development twice per week using a
caliper. Tumor volumes were determined using the
formula: volume = 1/2 × length × width2.
RNA sequencing
Total RNA was isolated from shControl and shADAM12
SUM159PT cells ± doxycycline (n = 3 for each condition)
using the Qiagen RNeasy purification kit and on-column
DNase I digestion according to the manufacturer’s pro-
tocols. The RNA was sent to the Kansas State University
Integrated Genomics Facility for quality assessment
using the Agilent 2100 Bioanalyzer and library prepar-
ation. An NGS library was generated for each RNA
sample using the Illumina TruSeq Library Prep kit. The
libraries were analyzed at the University of Kansas
Medical Center Genome Sequencing Facility on an
Illumina HiSeq 2500 with 100 bp single reads. All se-
quence analysis was performed using the CLC Genomics
Workbench version 8.0 (CLC Bio). The reads were
trimmed based on the quality score with a limit of 0.05
and ambiguous nucleotides were trimmed from the ends
with 2 set as the maximum number of ambiguities
allowed. Additionally, sequences shorter than 15 nt or
longer than 1000 nt were eliminated. Mapping to the
human genome (hg19) was performed using the RNA-
Seq Analysis tool and the following settings: map to
gene regions only, mismatch cost = 2, insertion and dele-
tion costs = 2, length and similarity fractions = 0.8, and
maximum number of hits for a read = 1. The expression
value was calculated as Reads Per Kilobase of transcript
per Million mapped reads (RPKM). The RPKM values
were statistically analyzed using the Empirical analysis of
Digital Gene Expression tool (EDGE) and FDR corrected
P-values were calculated. Genes that were significantly
changed by ADAM12 knockdown were further evalu-
ated by QIAGEN’s Ingenuity® Pathway Analysis (IPA®)
using the Canonical Pathways and Upstream Regulator
features. RNA sequencing data have been deposited to
the NCBI Sequence Read Archive (SRA) and are avail-
able at the accession number SRP077683.
Data mining
Expression levels of ADAM12 (transcript variant 1,
NM_003474) in 295 breast tumors from the NKI dataset
were retrieved from the Computational Cancer Biology
website at The Netherlands Cancer Institute (http://
ccb.nki.nl/data/) as ratios of fluorescence intensities to
the intensity of a reference pool [31]. Tumors were
assigned to individual subtypes of breast cancer according
to ref. [32]. Expression data for ADAM12 in 508 breast
invasive carcinomas from The Cancer Genome Atlas
(Nature 2012 dataset) [33] were accessed via the cBio-
Portal for Cancer Genomics (http://www.cbioportal.org/
public-portal/) [34, 35]. Since cBioPortal contains only
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gene-level data and it does not contain probe-level data,
ADAM12 expression values obtained through cBioPortal
represent merged data for different ADAM12 splice
variants. P-values for a t-test of ADAM12 expression
in each TNBC subtype versus all other TNBC sub-
types were retrieved from ref. [36]. The list of genes
whose expression was most highly correlated with the
expression of the ADAM12 gene was acquired from
the TCGA (Nature 2012 dataset) via the cBioPortal
using the mRNA co-expression feature. Overlaps
between ADAM12-correlated genes and gene sets
from the MSigDB collection were computed using the
GSEA website (http://software.broadinstitute.org/gsea/
msigdb/annotate.jsp).
Calculation of the ADAM12, CSC, and EGFR gene
expression signature scores
Genes (n = 45) significantly changed after ADAM12
knockdown in SUM159PT cells (Fig. 5b and Additional
file 1: Table S5) were used to construct an ADAM12
gene expression signature. Genes (355 different genes
corresponding to 493 individual transcripts) significantly
upregulated or downregulated in CD44hi/CD24-/lo sub-
populations of primary breast cancer cells and in cancer
mammospheres [22] were used to calculate the CSC sig-
nature scores. Expression values for these CSC-related
genes in 51 different breast cancer cell lines were
retrieved from Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/), using accession number
GSE69017. The top 250 genes whose expression was
most significantly changed upon stable expression of
EGFR in MCF7 cells [37] were used to calculate EGFR-
responsive gene signature scores. Expression values for
these EGFR-regulated genes were retrieved from GEO,
using accession number GSE3542. The expression values
for ADAM12-, CSC-, and EGFR-related genes in breast in-
vasive carcinomas were extracted from TCGA (Cell 2015
dataset) [38] via the cBioPortal (http://www.cbioportal.org/
public-portal/). The signature scores were then calculated
for all tumors for which gene expression values were avail-
able (a total of 421 tumors) as:
s ¼
X
i
wixi=
X
i
wij j
where w is the weight +1 or –1, depending on
whether the gene was upregulated or downregulated
in the signature, and x is the normalized gene expres-
sion level.
Survival analysis
The effect of ADAM12 expression on relapse-free sur-
vival rates of breast cancer patients was assessed using
the Kaplan-Meier Plotter (http://kmplot.com/analysis/).
This online tool uses manually curated database
containing gene expression data and relapse free and
overall survival information downloaded from GEO, the
European Genome-Phenome Archive (EGA), and TCGA
[39]. The parameters were set as follows: Affymetrix
probeset: 202952_s_at (as this probeset is specific for
ADAM12 transcript variant 1, encoding ADAM12-L);
Auto select best cutoff: On; Use array quality control:
Remove redundant samples, Exclude outlier arrays;
Check proportional hazards assumption: On; Restrict
analysis to subtypes: All, or ER-negative (derive ER
status from gene expression data: On), PR-negative,
HER2-negative, or Mesenchymal stem-like; Restrict ana-
lysis to selected cohorts: none; Database release: 2017;
Datasets: all.
Results
ADAM12 expression is upregulated in claudin-low breast
tumors and in cell populations enriched for breast cancer
stem cell-like cells
By analyzing gene expression profiles of 337 breast tu-
mors from the University of North Carolina database,
we previously noted that ADAM12 mRNA levels (tran-
script variant 1 encoding ADAM12-L protein isoform,
but not transcript variant 2 encoding ADAM12-S) were
significantly elevated in the claudin-low subtype of
breast cancer [18]. Here, we extended our observations
to two other tumor gene expression repositories: the
Netherlands Cancer Institute database (NKI, 295 breast
cancers) [31] and The Cancer Genome Atlas database
(TCGA, 508 breast cancers) [33]. In the NKI database,
ADAM12 mRNA levels (transcript variant 1) were more
frequently upregulated in claudin-low (CL) tumors
compared to basal (B), luminal A/B (LumA/B), HER2-
enriched (HER2+), or normal-like (NL) cancers
(Additional file 2: Figure S1a). Similarly, ADAM12 mRNA
expression levels in the TCGA database (retrieved as
merged values for different splice variants) were signifi-
cantly higher in claudin-low tumors than in other tumor
subtypes (Additional file 2: Figure S1b). Furthermore,
among different subtypes of TNBCs [36], ADAM12
mRNA levels (transcript variant 1) were previously found
significantly elevated (P = 5.19E-08) in the mesenchymal
stem-like (MSL) subtype compared to the mesenchymal
(M), basal-like 1 (BL1), basal-like 2 (BL2), immunomodu-
latory (IM), or luminal androgen receptor (LAR) subtypes
(Additional file 1: Table S2). Notably, the MSL subtype
shares many features with the claudin-low subtype of
breast cancer, including high expression of EMT- and
CSC-related genes [40].
Investigation of the top 40 genes which are most
closely correlated with ADAM12 expression in breast in-
vasive carcinomas from the TCGA database (Additional
file 1: Table S3) revealed a very significant enrichment
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(P = 7.43E-50) in the EMT hallmark signature from the
Gene Set Enrichment Analysis/Molecular Signature
Database (GSEA/MSigDB, ref. [41]) (Additional file 1:
Table S4). These findings corroborate a recent report, in
which ADAM12 mRNA expression was correlated with
EMT markers N-cadherin, vimentin, and TGFβ, but not
E-cadherin, in a panel of human breast cancer cell lines
and in 79 breast cancer biopsies [17].
Here, we examined ADAM12 protein levels in
several cell lines representing different intrinsic sub-
types of breast cancer: claudin-low cell lines Hs578T,
SUM1315MO2, BT549, and SUM159PT, basal cell
lines SUM102PT and SUM149PT, and luminal cell
lines MCF-7 and SUM225CWN [19]. Cell surface
levels of ADAM12-L were evaluated by flow cytometry
after staining of live cells with an antibody specific for
the extracellular domain of ADAM12-L (Fig. 1a). Also,
total cellular levels of ADAM12-L, after partial purifi-
cation on concanavalin A agarose, were detected by
Western blotting using an antibody specific for the
cytoplasmic domain of ADAM12-L (Fig. 1b). The spe-
cificity of ADAM12 bands was confirmed after
ADAM12 knockdown using an inducible shRNA con-
struct (see below). In accordance with ADAM12
mRNA expression data [17, 42], ADAM12-L protein
(from now on referred to as ADAM12) was most abun-
dantly expressed in claudin-low cell lines.
Since the gene expression signatures of claudin-low
tumors and claudin-low cell lines show a significant
similarity to the signature of CSCs [20, 22], we examined
the relationship between ADAM12 mRNA expression
and the CSC signature scores in a panel of 51 breast
cancer cell lines from Neve at al. [26]. The CSC scores
were calculated based on the genes whose expression
was most significantly changed in CD44hi/CD24-/lo pop-
ulations and in mammosphere-forming cells, as reported
by Creighton et al. [22] and described in Methods. As
shown in Fig. 1c, there was a significant positive correl-
ation between CSC scores and ADAM12 mRNA levels
(P = 1.4E-07).
One of the characteristic features associated with the
CSC phenotype is the resistance to anoikis, an apoptotic
cell death upon matrix detachment. When SUM159PTcells
were grown as mammospheres in ultra-low attachment
plates in serum-free medium, ADAM12 was more abun-
dant in mammospheres than in attached cells grown as
monolayers (Fig. 1d, see also [18]). Since mammosphere-
forming cells are largely anoikis-resistant, this result
suggested that ADAM12 expression might be upregulated
in breast CSCs.
Another characteristic feature of CSCs is their resist-
ance to chemotherapy. It was shown previously that
overexpression of ADAM12 in MCF10A cells, a non-
transformed human breast epithelial cell line, increased
cell resistance to cisplatin [17]. Here, we asked whether
cells with high endogenous expression of ADAM12
would preferentially survive treatment with a chemo-
therapeutic agent. To this end, non-confluent adherent
cultures of SUM159PT cells were treated for 6 days with
10 nM paclitaxel, which induced death in ~90% of cells.
The surviving ~10% of cells were subsequently incu-
bated for 6 additional days in the absence of paclitaxel,
during which they resumed proliferation (a “recovery
phase”). In DMSO-treated cultures, ~1.5% of cells
expressed ADAM12 at the level that was equal to or
exceeded an arbitrarily defined “high” expression level
(ADAM12hi), whereas in paclitaxel-treated cultures, the
percentage of ADAM12hi cells was increased ~3-fold
(Fig. 1e and Additional file 3: Figure S2). This result
indicated that cells with high expression of ADAM12
might be more chemoresistant than cells with lower
ADAM12 expression, as it appears that they preferen-
tially survived paclitaxel treatment.
Using fluorescence-activated cell sorting, we next iso-
lated two subpopulations of SUM159PT cells: ADAM12hi
representing ~1.5% of cells with the highest cell surface
expression of ADAM12, and ADAM12med representing
cells with medium ADAM12 expression levels (Additional
file 4: Figure S3). ADAM12hi cells grew slower than
ADAM12med cells under standard 2D conditions in
complete growth medium (doubling time 19 ± 0.9 h versus
14 ± 0.2 h, P < 0.0001, Additional file 5: Figure S4a). How-
ever, ADAM12hi cells formed more primary and second-
ary mammospheres than ADAM12med cells (Additional
file 5: Figure S4b). ADAM12hi cells also expressed higher
levels of several CSC markers, mesenchymal markers, and
cancer drug resistance genes than ADAM12med cells
(Additional file 5: Figure S4c-e, respectively). These results
indicated that, in SUM159PT cells, a subpopulation char-
acterized by high endogenous expression levels of
ADAM12 was enriched in features commonly attributed
to CSCs.
ADAM12 knockdown reduces stem cell-like features of
breast cancer cells in vitro
To examine whether ADAM12 plays an active role in sup-
porting the CSC phenotype, we first examined the effect
of ADAM12 knockdown on cell migration, invasion, and
mammosphere formation using a doxycycline-inducible
shRNA system. ADAM12 shRNA (shADAM12) or con-
trol shRNA (shControl) cloned into pInducer10 vector
(Additional file 6: Figure S5a) was stably transduced into
SUM159PT cells. Treatment with 1 μg/ml doxycycline for
4 days significantly decreased the level of ADAM12
mRNA (Additional file 6: Figure S5b) and protein
(Additional file 6: Figure S5c, d) in SUM159PT_shA-
DAM12 cells, but not in SUM159PT_shControl cells.
ADAM12 knockdown did not have a significant effect
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Fig. 1 ADAM12 expression is upregulated in claudin-low breast cancer cells and in subpopulations enriched for CSCs. a. Cell surface expression of
ADAM12 protein in breast cancer cell lines was evaluated by flow cytometry. Red, anti-ADAM12 antibody staining; gray, isotype control antibody
staining. b Total cellular expression of ADAM12 was analyzed by Western blotting after partial purification of ADAM12 on concanavalin A (conA)
agarose, as described [42]. GAPDH in the input fractions shows comparable conA agarose loading for all cells. Arrow, the nascent full length
ADAM12; arrowhead, the processed form lacking the N-terminal pro-domain. c CSC signature score versus ADAM12 mRNA expression in 51 breast
cancer cell lines. The CSC signature scores were calculated based on ref. [22] and microarray expression data retrieved from GEO:GSE69017, as
described in Methods. Cell lines analyzed in panels a and b are shown in red. d ADAM12 protein levels in total lysates of SUM159PT cells grown
as attached monolayers or as mammospheres, analyzed by Western blotting. Arrow, the nascent full length ADAM12; arrowhead, the processed
form lacking the N-terminal pro-domain; *, a non-specific band. Positive control represents ADAM12 after partial purification on conA agarose.
e Cell surface expression of ADAM12 in SUM159PT cells treated for 6 days with DMSO (control) or with 10 nM paclitaxel (PTX), and then allowed
to recover for 6 days without PTX, was examined by flow cytometry. The population of cells with the highest expression of ADAM12 is shown in
red. FSC, forward scatter
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on cell proliferation or survival rates (results not shown).
In the Transwell migration assay, SUM159PT_shA-
DAM12 cells treated with doxycycline were less motile
than untreated cells (Fig. 2a). In three-dimensional Matri-
gel cultures, doxycycline-treated SUM159PT_shADAM12
cells were less invasive than shADAM12 cells incubated
without doxycycline (Fig. 2b). Doxycycline treatment did
not have a significant effect on the migration or invasion
of SUM159PT_shControl cells (Fig. 2a, b). Furthermore,
induction of ADAM12 knockdown decreased the ability
of SUM159PT cells to survive under detachment condi-
tions. Using an apoptosis assay based on measuring DNA
fragmentation by ELISA, we observed an increased amount
of cell death in doxycycline-treated detached SUM159PT_-
shADAM12, but not in SUM159PT_shControl cells
(Fig. 2c). Accordingly, the number of mammospheres
formed by doxycycline-treated SUM159PT_shADAM12
cells was lower than the number of mammospheres formed
by untreated SUM159PT_shADAM12 cells or by
SUM159PT_shControl cells (Fig. 2d). Thus, ADAM12
knockdown decreased the migration, invasion, anoikis-
resistance, and mammosphere-forming potential of
SUM159PTcells.
Breast CSCs are characterized by high levels of alde-
hyde dehydrogenase (ALDH) activity and have CD44hi/
CD24-/lo cell surface marker profile [23, 43]. To evaluate
the effect of ADAM12 knockdown on ALDH (measured
as ALDEFLUOR+ cells), CD44, and CD24 expression, we
used flow cytometry-based assays. To minimize possible
inaccuracies that might be introduced during compensa-
tion protocols (required to correct for spectral overlaps
between different fluorochromes and a strong fluores-
cence signal of red fluorescent protein (RFP), which was
co-expressed with shRNAs from the pInducer10 vector),
we used siRNA transfection to knockdown ADAM12.
First, SUM159PT cells were transfected with a pool of
four siRNAs targeting ADAM12, all of which had differ-
ent ADAM12-targeting sequences than shADAM12.
Fig. 2 ADAM12 knockdown reduces cell migration, invasion, resistance to anoikis, and sphere formation. SUM159PT cells expressing inducible
ADAM12 shRNA (shADAM12) or control shRNA (shControl) were treated with doxycycline (Dox; 1 μg/ml) for 4 days. a Cell migration was analyzed
using Transwell assays. The data are shown as means ± SEM from 3 determinations. n.s., non-significant, P > 0.05. b Representative phase-contrast
images of SUM159PT_shADAM12 and SUM159PT_shControl cells embedded in 3D Matrigel. Scale bar, 100 μm. c Anoikis (apoptotic cell death
upon detachment) was assayed using a DNA fragmentation ELISA kit. A time course of cell death was measured in triplicates (raw data, left), and
the mean values of DNA fragmentation, ±SEM, after 24 h of detachment obtained in three independent experiments were calculated (right).
*, P < 0.05. d Sphere formation was evaluated after seeding single-cell suspensions in serum-free sphere medium containing 1% methylcellulose
into ultra-low attachment plates. After 7 days, spheres with diameters >50 μm were photographed and counted using ImageJ. The results are
shown as mean fold change in sphere numbers after doxycycline treatment, normalized to shControl cells without doxycycline, ±SEM, obtained
in 3 independent experiments
Duhachek-Muggy et al. Molecular Cancer  (2017) 16:32 Page 8 of 18
Downregulation of ADAM12 at the cell surface was con-
firmed by flow cytometry (Additional file 7: Figure S6a).
The amount of ALDEFLUOR+ cells was decreased ~3-
fold in siADAM12-transfected SUM159PT cells com-
pared to siControl-transfected cells (Fig. 3a-c). A similar
effect of ADAM12 knockdown was observed in Hs578T
cells, in which the number of ALDEFLUOR+ cells was di-
minished ~2-fold upon siADAM12 transfection (Fig. 3d).
An efficient ADAM12 knockdown in siADAM12-
transfected Hs578T cells was confirmed by flow cytometry
(Additional file 7: Figure S6b).
ADAM12 knockdown using pooled siRNAs resulted in
a significant reduction of the CSC-containing CD44hi/
CD24-/lo population and expansion of the non-CSC
CD44hi/CD24+ population in SUM159PT cells (Fig. 3e, f )
and Hs578T cells (Fig. 3g). Increased expression of CD24
(and thus an expansion of the non-CSC population) was
also observed in shADAM12-expressing SUM159PT cells
treated with doxycycline, but not in shControl-expressing
SUM159PT cells upon the same treatment (Additional
file 8: Figure S7a and b, respectively).
ADAM12 knockdown decreases tumor initiating potential
in mouse xenografts in vivo
To examine the role of ADAM12 in tumor initiation in
vivo, we performed limiting dilution transplantation
experiments. SUM159PT_shADAM12 or SUM159PT_sh-
Control cells, pre-treated with doxycycline or vehicle,
were injected into NOD-SCID mice as a 10-fold dilution
series from 1x104 to 1x102 cells per mammary gland. Mice
injected with doxycycline-treated cells were maintained
on a doxycycline-containing diet for continuous expres-
sion of shRNA. Mice injected with vehicle-treated cells
were maintained on a doxycycline-free diet. After moni-
toring mice for 21 days for tumor formation, the fre-
quency of CSCs among SUM159PT_ shADAM12 cells
without or with doxycycline treatment was estimated as
~1/6,808 and ~1/18,399 cells, respectively, using the
Fig. 3 ADAM12 knockdown reduces the ALDEFLUOR+ subpopulation and diminishes the CD44hi/CD24-/lo subpopulation of cells. a, b SUM159PT
cells were transfected with a pool of four control siRNAs (siControl, a) or a pool of four ADAM12 siRNAs (siADAM12, b) and analyzed three days
later by flow cytometry. Plots show side cell scatter (SSC) versus BAA- fluorescence (BODIPY-aminoacetate, an intracellular reaction product of
aldehyde dehydrogenase). ALDEFLUOR- (blue) and ALDEFLUOR+ (red) gates were identified after pre-treatment of cells with DEAB, an ALDH
inhibitor. c, d Percentages of ALDEFLUOR+ populations in SUM159PT (c) and Hs578T (d) cells were determined in at least four independent
experiments; shown are means ± SEM. e SUM159PT cells transfected with pooled siRNAs were stained with anti-CD24-PE and anti-CD44-APC
antibodies and analyzed by flow cytometry. f, g Percentages of CD44hi/CD24-/lo populations in SUM159PT cells (f) and Hs578T cells (g) were
determined in at least three independent experiments; shown are means ± SEM
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ELDA algorithm [44] (P-value of the difference between
groups 0.156; Fig. 4a). Among SUM159PT_shControl
cells, without or with doxycycline treatment, the fre-
quency of CSCs was estimated as ~1/8,447 and ~1/
4,885 cells, respectively (P = 0.359; Fig. 4a). The differ-
ence in CSC frequencies between shADAM12 and
shControl cells in doxycycline-treated mice was statis-
tically significant (P = 0.042, Fig. 4a).
In another approach, 1x105 cells were injected into
mouse mammary glands, and tumor growth rates were
monitored for up to 38 days. Tumors formed by
SUM159PT_shADAM12 cells in doxycycline-treated
mice were significantly smaller than tumors detected in
untreated mice (P < 0.0001; Fig. 4b, c). There was no
statistical difference between the growth rates of tumors
formed by SUM159PT_shControl cells in doxycycline-
treated and untreated mice (Fig. 4d, e). Collectively,
these results suggested that ADAM12 knockdown
decreased both tumor initiation and tumor growth in
mice in vivo.
Fig. 4 ADAM12 knockdown reduces tumor formation in NOD-SCID mice after orthotopic cell transplantation. a Tumor incidence in the limiting
dilution transplantation assay. SUM159PT_shADAM12 and SUM159PT_shControl cells were transplanted in the fourth mammary fat pad of
NOD-SCID mice in limiting dilutions (10,000, 1,000, or 100 cells per injection site). Prior to transplantation, cells were pre-treated with doxycycline
(Dox; 1 μg/ml) for 4 days, and doxycycline (2 g/kg) was then continually administered in the diet. The presence of palpable tumors was determined
3 weeks after cell transplantation. The frequency of breast tumor initiating cells (BTICs) and P-values for the statistical significance between groups were
calculated using extreme limiting dilution analysis (ELDA, http://bioinf.wehi.edu.au/software/elda/; ref. [44]). b, d Representative tumors 38 days after
injection of 105 SUM159PT_shADAM12 cells (b) or SUM159PT_shControl cells (d). c, e Tumor growth was monitored for 0-38 days. Nonlinear regression
curves were fitted using GraphPad software
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Global changes in gene expression upon ADAM12
knockdown
To gain insight into global gene expression networks
regulated by ADAM12 in breast cancer cells, we per-
formed RNA sequencing of SUM159PT_shADAM12
and SUM159PT_shControl cells, before and after doxy-
cycline treatment. We used two types of comparisons to
identify ADAM12-regulated genes (Fig. 5a). First, using
a cut-off for | fold change| >1.2 and False Discovery Rate
(FDR)-adjusted P <0.05, we identified 340 genes that
were differentially expressed in SUM159PT_shADAM12
cells with versus without doxycycline treatment and 96
genes that were significantly altered in SUM159PT_sh-
Control cells by doxycycline treatment. Eighty-six genes
that were common to these two gene lists were removed
from further analysis because their expression was, pre-
sumably, affected by doxycycline. Second, we identified
175 genes that were differentially expressed between
SUM159PT_shADAM12 versus SUM159PT_shControl
cells, in the presence of doxycycline and 100 genes that
were differentially expressed in these cells in the absence
of doxycycline. Seventy-three genes that were present in
both gene sets were removed from further analysis be-
cause they presumably represented intrinsic variations
between SUM159PT_shADAM12 and SUM159PT_sh-
Control cells. Finally, by combining these two analyses,
we generated a high confidence list of 45 genes that
were consistently changed in both comparisons and
showed the same direction of change (Fig. 5a). Among
these, 25 genes were downregulated and 20 genes were
upregulated in response to ADAM12 knockdown
(Fig. 5b, Additional file 1: Table S5). An ADAM12 gene
expression signature score derived from the expression
levels of these 45 genes was significantly correlated with
ADAM12 expression in breast tumors from the TCGA
database (P = 2.6E-14, Fig. 5c). Remarkably, there was
also a significant positive correlation between the
ADAM12 score and the CSC score in the same tumor
dataset (P = 2.1E-15, Fig. 5d).
Biological pathways related to the ADAM12-regulated
transcripts
We computed overlaps of the 45 genes altered after
ADAM12 knockdown with gene sets from GSEA/MSigDB
(http://www.broadinstitute.org/gsea/msigdb). We noted
that genes downregulated after ADAM12 knockdown sig-
nificantly overlapped with genes transiently induced by
EGF [45] (CD55, IER3, ITGA2, MCL1, SERPINE1,
ZFP36L1; P = 1.95E-09), and genes constituting HRAS
oncogenic signature [46] (CD55, EREG, IER3, ITGA2,
MCL1; P = 2.75E-07) (Additional file 1: Table S6).
To further determine which canonical signaling path-
ways might have been over-represented among ADAM12-
regulated genes, we used Ingenuity Pathway Analysis
(IPA, http://www.ingenuity.com). Canonical pathways
analysis identified “Signaling by Rho Family GTPases”
as the only pathway that was significantly enriched
(P = 1.25E-04) among genes altered in response to
ADAM12 knockdown and had a non-zero (negative) z-
score (Additional file 9: Figure S8), indicating that this
pathway might have been downregulated after ADAM12
knockdown. To better understand gene expression
changes observed in response to ADAM12 knockdown,
we applied the IPA Upstream Regulator analysis. The goal
of the IPA Upstream Regulator analysis is to identify a
cascade of upstream transcriptional regulators that can
explain the observed gene expression changes in a user’s
dataset [47]. This approach indicated that there was a
statistically significant overlap between genes altered after
ADAM12 knockdown and the genes regulated by LPS,
SP1, EGFR, MTOR, SMARCA4 and NEDD9 tran-
scriptional regulators (Fig. 5e). Among those, an over-
lap between ADAM12-modulated genes and genes
changed in response to EGFR inhibition was the most
significant (P = 3.97E-09).
ADAM12 supports the CSC phenotype via modulation of
the EGFR pathway
Our investigation of genes changed in response to
ADAM12 knockdown in SUM159PT cells using GSEA/
MSigDB and IPA gene sets consistently pointed to alter-
ations in the EGFR pathway. Therefore, we tested a
hypothesis that ADAM12 supports the CSC phenotype
via modulation of the EGFR pathway. First, we examined
the effect of erlotinib, a specific inhibitor of EGFR, on
SUM159PT cells. Treatment of SUM159PT cells with
1 μM erlotinib inhibited the basal phosphorylation level
of EGFR at Y1068, one of the major phosphorylation
sites in response to ligand-mediated EGFR activation
(Fig. 5f ). Importantly, erlotinib elicited a similar effect
on the CD44hi/CD24-/lo cell population as ADAM12
knockdown did (Fig. 5g, h), suggesting that ADAM12
knockdown might have indeed resulted in inhibition of
EGFR signaling.
Next, we examined the effect of ADAM12 knockdown
on the basal activation level of EGFR. We observed that
incubation of SUM159PT_shADAM12 cells, but not
SUM159PT_shControl cells, with doxycycline, or trans-
fection of SUM159PT cells with pooled ADAM12
siRNAs decreased the level of EGFR phosphorylation at
Y1068 by ~40% and ~55%, respectively (Fig. 6a). Similar
results were obtained for Hs578T cells, although the ef-
fects were somewhat more modest than in SUM159PT
cells (Fig. 6b). Thus, ADAM12 is a positive regulator of
EGFR in both cell lines.
Activation of EGFR at the basal level and its suscepti-
bility to inhibition by erlotinib suggested the presence of
EGF-like ligands in culture medium. These ligands
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might have been endogenously expressed by cells and
released from the cell surface by ADAM12 and, possibly,
other ADAM proteases. Alternatively, low concentra-
tions of EGF-like growth factors might be present in the
serum used to supplement culture media. To discrimin-
ate between these two possibilities, cells were incubated
for 24 h with batimastat (BB-94), a metalloprotease in-
hibitor, in serum-free medium or in complete medium
Fig. 5 RNA sequencing analysis of the gene expression changes induced by ADAM12 knockdown in SUM159PT cells. a Diagram summarizing the
design and the outcome of the RNA-Seq experiment. b Heatmaps of differentially expressed genes in response to ADAM12 knockdown. Compared
are SUM159PT_shADAM12 cells without versus with doxycycline treatment (left) and SUM159PT_ shControl versus SUM159PT_ shADAM12 cells
treated with doxycycline (right). c ADAM12 gene expression signature score versus ADAM12 mRNA expression in 421 breast invasive carcinomas from
the TCGA database (Cell 2015 dataset). ADAM12 signature scores were generated based on the expression of 45 ADAM12-regulated genes shown in
panel b. d CSC signature score versus ADAM12 score in 421 breast invasive carcinomas from the TCGA database (Cell 2015 dataset). CSC signature
scores were generated based on ref. [22], as described in Methods. e Results of the IPA Upstream Regulator analysis. Potential upstream regulators
with an overlap P‐value < 0.05 and an activation |z score| > 2 are shown. f Immunoblot analysis of SUM159PT cells after incubation for 24 h in complete
media in the presence or absence of 1 μM erlotinib, an EGFR inhibitor, followed by 30 min treatment with 20 ng/ml EGF, as indicated. g, h EGFR
inhibition mimics the effect of ADAM12 knockdown on the CD44hi/CD24-/lo cell population. SUM159PT cells grown in complete medium were treated
for 3 days with DMSO or 1 μM erlotinib. g CSC-containing CD44hi/CD24-/lo population (green) was identified by flow cytometry. h Percentage of CD44hi/
CD24-/lo populations was determined in three independent experiments
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containing serum. Regardless of the presence or absence
of serum, treatment with BB-94 decreased the phosphor-
ylation level of EGFR by 70-80% (Fig. 6c). These results
indicated that the basal activation of EGFR was achieved
through interactions with endogenous EGF-like ligands
that were released from cells via ADAM-mediated cleav-
age and that were acting in an autocrine/paracrine
manner.
To further determine whether ADAM12 played a role
in EGFR activation in response to endogenous ligands,
we examined the effect of BB-94 or exogenously added
EGF on EGFR phosphorylation in cells transfected with
control or ADAM12 siRNAs. In these experiments, we
used two individual siRNAs from the pool of four siR-
NAs targeting ADAM12, which diminished cell surface
expression of ADAM12 with the highest potency,
namely siADAM12#1 and #2, (Additional file 7:
Figure S6c). These two individual siRNAs reduced the
level of pEGFR_Y1068 by ~50% (Fig. 6d), as seen
before with shRNA or pooled siRNAs. Importantly,
the effects of siADAM12 #1 and siADAM12 #2 on
pEGFR_Y1068 were significantly reduced or elimi-
nated when cells were further incubated with 10 μM
BB-94 or 20 ng/ml of EGF (Fig. 6d). These results
supported a model in which ADAM12 sustained the
basal level of activation of EGFR by mediating the re-
lease of endogenous EGF-like ligands.
Since claudin-low tumors have elevated activities of
the EGFR pathway [20], we next asked whether re-
duced activation of EGFR in ADAM12-deficent cells
Fig. 6 ADAM12 knockdown reduces the basal level of EGFR activation. a SUM159PT_shADAM12 or SUM159PT_shControl cells were incubated for
4 days in the presence or absence of 1 μg/ml of doxycycline. Alternatively, SUM159PT cells were transfected with a pool of four control siRNAs
(siControl) or a pool of four ADAM12 siRNAs (siADAM12) and analyzed three days later by Western blotting. b Hs578T_shADAM12, Hs578T
_shControl, or parental Hs578T cells were treated and analyzed as in panel a. c The effect of batimastat (BB-94) on the basal activation level of
EGFR. SUM159PT cells were incubated for 24 h with 0, 10 μM, or 50 μM BB-94, in the absence or presence of serum, as indicated. d The effect of
ADAM12 knockdown on the activation of EGFR is abolished by BB-94 or exogenous EGF. SUM159PT cells were transfected with control siRNAs
or with two individual ADAM12 siRNAs. Two days after transfection, cells were incubated in complete media supplemented with 10 μM BB-94
for additional 24 h. Alternatively, three days after transfection, cells were incubated for 30 min with 20 ng/ml EGF. In a-d, representative blots
are shown and relative changes in pEGFR/EGFR (means ± SEM; n = 3) are indicated; values significantly lower than 1 (P < 0.05) are shown in red.
e qRT-PCR analysis of the indicated transcripts in SUM159PT_shADAM12 or SUM159PT_shControl cells incubated for 4 days in the presence or
absence of 1 μg/ml of doxycycline. Expression was normalized to β-ACTIN and is shown as fold change after doxycycline treatment; 3≤n≤5
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might directly impact the expression of genes associated
with claudin-low tumors and cell lines. Indeed, we ob-
served that the expression of several claudin-low-enriched
transcripts, ALDH1A1, IL8, SERPINE1, VCAM1, and
CD44 [19], was decreased in doxycycline-treated
SUM159PT_shADAM12 cells versus SUM159PT_shCon-
trol cells (Fig. 6e). These results underscore the role of
ADAM12 in promoting the claudin-low phenotype, which
is associated with the CSC features.
To determine whether modulation of the EGFR path-
way by ADAM12 is prerequisite for the ADAM12-medi-
ated effect on CSC features, cells were transfected with
siADAM12, treated for two days with exogenous EGF,
and the cell surface expression of CD44/CD24 markers
was evaluated by flow cytometry. Importantly, while
EGF increased the pool of CD44hi/CD24-/lo cells, as ex-
pected, ADAM12 knockdown did not have any effect on
CD44 or CD24 expression in the presence of EGF
(Fig. 7a). These results suggested that downregulation of
EGFR activation by ADAM12 knockdown was required
for a reduction of CSC-containing CD44hi/CD24-/lo cell
population.
We further explored the relationships between
ADAM12 expression and the EGFR-responsive gene sig-
nature scores in 421 tumors from the TCGA database.
The EGFR scores were calculated based on the gene
expression profiling of MCF-7 breast cancer cells over-
expressing EGFR [37]. We observed positive correlations
between ADAM12 and the EGFR score (P = 3.2E-13,
Fig. 7b). Importantly, ADAM12 expression itself was not
significantly changed by manipulations of EGFR in
MCF-7 cells [37].
Based on our results, we propose a model where
ADAM12 contributes to the activation of EGFR by re-
leasing EGF-like ligands from the cell surface, and ultim-
ately to the expansion of CSC populations. As the EGFR
signaling pathway is frequently activated in TNBC,
ADAM12-mediated increase of EGFR activity should be
Fig. 7 ADAM12 supports the CSC phenotype via modulation of the EGFR pathway. a Activation of EGFR by exogenous EGF bypasses the effect of
ADAM12 knockdown on the reduction of CD44hi/CD24-/lo cell population. SUM159PT cells were transfected with a pool of four control siRNAs
(siControl) or a pool of four ADAM12 siRNAs (siADAM12). After 24 h, cells were incubated with or without 20 ng/ml EGF in complete media for
additional 48 h and analyzed for CD44 and CD24 expression. b EGFR responsive gene signature score versus ADAM12 mRNA expression in 421 breast
invasive carcinomas from the TCGA database (Cell 2015 dataset). EGFR signature scores were calculated based on ref. [37]. c Relapse-free survival (RFS)
rates for breast cancer patients stratified by ADAM12 expression levels were estimated using Kaplan-Meier Plotter (http://kmplot.com/analysis/) [39].
Shown are all tumors, triple-negative (TN) tumors, or tumors classified as mesenchymal stem-like (MSL). Hazard ratio (HR), 95% confidence interval,
P-values, and numbers of patients are also included
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the most relevant in this type of cancer. Our model is
further supported by the fact that high expression of the
ADAM12 gene correlates with poor prognosis in 196
patients with TNBC and, most importantly, in 59
patients with the MSL subtype of TNBC, but not in a gen-
eral breast cancer patient population (Fig. 7c, assessed by
the Kaplan-Meier Plotter online tool, ref. [39]).
Discussion
The EGFR pathway activation has been frequently ob-
served in claudin-low TNBCs and cell lines bearing
CSC-like features [20], and several reports indicated
that EGFR is a positive regulator of CSCs. For
example, stimulation of the EGFR pathway promoted
mammosphere formation by normal breast stem cells
and by ductal carcinoma in situ (DCIS)-derived
epithelial cells [48]. Recently, it has been reported
that cetuximab, a monoclonal anti-EGFR antibody, re-
duced mammosphere formation and CSC populations
in breast cancer cells in vitro and potentiated the
effect of Ixabepilone, a new generation microtubule-
stabilizing agent, in treating orthotopic TNBC xeno-
grafts [49]. Furthermore, in A431 epidermoid cancer
cells, treatment with cetuximab upregulated the
expression of the epithelial markers E-cadherin and
occludin, downregulated the epithelial transcriptional
repressors Zeb, Snail, and Slug, and reduced the
CD44hi/CD24-/lo phenotype [50]. EGFR activation also
promoted acquisition of CSC properties in head and
neck squamous cell carcinoma [51, 52] and in naso-
pharyngeal carcinoma [53], pointing to a more
general function of EGFR in CSC biology.
The postulated mechanisms by which EGFR promotes
the CSC features in TNBC cells include the activation of
MEK/ERK signaling [54], the STAT3 pathway [21], and/
or autophagy [49]. For example, blocking ERK activation
in claudin-low cell lines by MEK inhibitors or by forced
expression of DUSP4, dual specificity phosphatase-4 that
is a negative regulator of ERK, has been shown to reduce
the CD44hi/CD24-/lo populations in vitro and to dimin-
ish tumor initiating populations in vivo [54]. STAT3,
which is another downstream effector of EGFR, has been
recently reported to be preferentially activated in tumor-
initiating cells/CSCs in claudin-low breast cancer [21],
raising a possibility that it might, at least partially, medi-
ate the downstream effects of EGFR on CSC properties
of claudin-low cells.
EGFR is activated by soluble ligands that are synthesized
as transmembrane precursors and need to be released
from the cell surface by ADAM proteases [5, 55]. In many
cell types and tissues, ADAM17 or ADAM10 act as
dedicated and robust EGFR ligand “sheddases” [1, 10].
Likewise, it has been postulated that ADAM17 is the main
ADAM responsible for EGFR ligand cleavage and
activation of EGFR in breast cancer [56–58]. However,
other ADAMs, including ADAM12, may mediate the re-
lease of soluble EGFR ligands as well. For example,
ADAM12 was shown to act as a sheddase for heparin-
binding EGF-like growth factor (HB-EGF) during cardiac
hypertrophy [59] and under hypoxia in head and neck,
lung, and pancreatic cancer cells, leading to the formation
of invadopodia and increasing cancer cell invasion [60].
Whether ADAM12 activates EGFR in breast cancer cells
and, in particular, whether ADAM12-mediated EGFR
activation promotes the acquisition of the breast CSC
phenotype, has not been sufficiently explored.
In this report, we have identified ADAM12 as a modi-
fier of the EGFR activation in claudin-low TNBC. In
existing microarray datasets, ADAM12 mRNA levels
were the highest in claudin-low and MSL TNBCs, and
they strongly correlated with the EMT hallmark gene
signature. Among breast cancer cell lines, claudin-low
cells expressed the highest levels of ADAM12. Down-
regulation of ADAM12 decreased the basal activation
levels of EGFR, diminished the expression of claudin-
low transcripts, reduced the CSC phenotype in vitro,
and decreased the tumorigenic potential of engrafted
cells in mice in vivo. In addition, ADAM12 mRNA
expression was strongly correlated with the EGFR activa-
tion score in 421 breast invasive cancers. Our previous
analysis of two clinical datasets showed that high expres-
sion of ADAM12 was predictive of resistance to neoad-
juvant chemotherapy in ER-negative breast cancer [18].
This is fully consistent with ADAM12 being an EMT-
and CSC-related gene, as both EMT and CSCs contrib-
ute to drug resistance [61, 62]. Finally, in a dataset of
196 TNBCs and 59 MSL TNBCs analyzed here, and pre-
viously in 53 TNBC patients without systemic treatment
[15, 16], high ADAM12 expression was associated with
decreased metastasis-free survival times.
Current treatments of TNBC rely mainly on chemo-
therapy, as there are no targeted therapies specifically
approved for this type of breast cancer [63]. EGFR is
expressed in 60-70% of TNBCs [64, 65], raising an early
hope for EGFR-targeted therapies in TNBC. Two com-
pleted clinical trials investigated the therapeutic poten-
tial of cetuximab, as a single agent or in addition to
cisplatin chemotherapy, in unselected TNBC patients
with metastatic disease [66, 67]. While the results have
been disappointing and there was no significant effect
on progression-free or overall patient survival, it is be-
coming clear that EGFR expression alone does not ne-
cessarily indicate tumor cell dependence on EGFR
signaling and further molecular stratifications and pa-
tient selections are needed in future trials [63, 68, 69].
We propose that ADAM12 may be an important
biomarker in identifying TNBCs with over-activation of
the EGFR pathway and may help select patients that
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would better respond to EGFR inhibitors. In addition,
further detailed studies of ADAM12-mediated regulation
of the EGFR pathway should establish whether
ADAM12 itself may be a suitable target for CSC-like
populations in claudin-low TNBC.
Conclusions
ADAM12 supports the CSC phenotype in claudin-low
breast cancer cells via modulation of the EGFR activation.
Therefore, ADAM12 may be an important biomarker in
identifying TNBCs that might respond to EGFR inhibition.
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Table S3. The list of top 40 genes correlated with ADAM12 expression
in breast invasive carcinomas from the TCGA database. Table S4. The list
of hallmark GSEA/MSigDB gene signatures enriched in the 40 genes from
Table S2. Table S5. The list of 45 genes changed by ADAM12
knockdown in SUM159PT cells. Table S6. Overlaps between ADAM12-
regulated genes and gene sets in GSEA/MSigDB. Table S7. qRT-PCR
primer
sequences. (PDF 76 kb)
Additional file 2: Figure S1. ADAM12 mRNA is upregulated in claudin-
low breast cancers. a Heatmap showing ADAM12 mRNA expression levels
in 295 breast cancer patients from the Netherlands Cancer Institute (NKI)
database [31]. Molecular subtypes of tumors are: B, basal; CL, claudin-low;
HER2+, HER2-enriched; LumA, luminal A; LumB, luminal B; NL, normal-like.
b Expression levels of ADAM12 in 508 breast cancer patients from The
Cancer Genome Atlas (TCGA, Nature 2012 dataset) [33]. (TIF 4437 kb)
Additional file 3: Figure S2. Histogram analysis of a representative
flow cytometry data showing the effect of 10 nM paclitaxel on ADAM12
expression in SUM159PT cells. Cells were treated for 6 days with DMSO
(control) or with 10 nM paclitaxel (PTX), and then allowed to recover for
6 days without PTX. Live cells were stained with anti-ADAM12 antibody and
propidium iodide (PI); only viable (PI-negative) cells were included in the
analysis. To further identify ADAM12-positive cells, histogram subtraction of
partially overlapping sample (anti-ADAM12 Ab) and control (isotype control
Ab) histograms was performed using the FCS Express 4 software. Median
fluorescence intensity of the resulting curves and the 5th and 95th
percentiles for DMSO- and PTX-treated cells are shown. (TIF 3184 kb)
Additional file 4: Figure S3. Sorting ADAM12hi and ADAM12med
subpopulations of SUM159PT cells. Live cells were stained with anti-
ADAM12 antibody and propidium iodide (PI). A population of ~1.5%
viable (PI-negative) cells with the highest expression of ADAM12,
ADAM12hi, and a population with medium expression levels of ADAM12,
ADAM12med, corresponding to the middle ~75% of all viable cells, were
sorted. A subsequent post-sort flow cytometry and qRT-PCR analyses
confirmed an enrichment of ADAM12hi and ADAM12med cells within
sorted populations. (TIF 221 kb)
Additional file 5: Figure S4. ADAM12hi subpopulation of SUM159PT
cells is enriched for cancer stem cell-like features. a Growth rates of
sorted ADAM12hi and ADAM12med populations of SUM159PT cells. Sorted
cells were plated in 96-well plates in triplicates and the
relative numbers of live cells were determined 24 h -72 h later using the
CellTiter-Glo viability assay. Graph represents mean values ± SEM from 2
independent experiments, as well as fitted exponential growth curves with
95% confidence interval. b Mammosphere formation by ADAM12hi and
ADAM12med populations. Sorted cells were plated in ultra-low attachment
plates in mammosphere medium containing 1% methylcellulose. After
10 days, primary (1o) mammospheres were collected, trypsinized, and single
cell suspensions were seeded for secondary (2o) mammosphere formation.
Mammospheres were visualized by phase contrast imaging, and the
numbers of spheres with diameters > 50 μm were counted using ImageJ.
The results are shown as means ± SEM obtained from 3 independent
experiments. c-e, Relative expression of cancer stem cell markers (c),
epithelial-to-mesenchymal transition markers (d), and cancer drug resistance
genes (e) in ADAM12hi versus ADAM12med subpopulations of SUM159PT
cells. Sorted cell populations were analyzed by qRT-profiling using RT2
Profiler PCR Arrays (Qiagen). Genes included in the arrays are shown in
black, the data for ADAM12 is shown in red. (TIF 1278 kb)
Additional file 6: Figure S5. Doxycycline-inducible ADAM12
knockdown in SUM159PT cells. a Diagram of the doxycycline-
inducible lentiviral shRNA construct targeting ADAM12. 5’-LTR, 5’-long ter-
minal repeat; TRE, tetracycline-inducible promoter; tRFP, turbo red fluores-
cent protein; miR30-5’ and shADAM12, micro-RNA-30-adapted shRNA
targeting ADAM12; Ubc, human ubiquitin C promoter; rtTA3, reverse
tetracycline-transactivator 3; IRES, internal ribosomal entry site; Puro, puro-
mycin resistance gene; 3’-LTR, 3’-long terminal repeat. b, c, d Validation of
ADAM12 knockdown. Stably transduced SUM159PT_shADAM12 and
SUM159PT_shControl cells were incubated for 4 days with or without
1 μg/ml of doxycycline. b ADAM12 mRNA levels were quantified by qRT-
PCR. c ADAM12 protein levels were determined by Western blotting after
glycoprotein enrichment on concanavalin A agarose. EGFR serves as a
loading control for glycoprotein-enriched fractions. Arrow, the nascent
full length ADAM12; arrowhead, the processed form lacking the N-
terminal pro-domain. d Cell surface expression of ADAM12 was examined
by flow cytometry. (TIF 1149 kb)
Additional file 7: Figure S6. ADAM12 knockdown using siRNAs. a
SUM159PT cells were transfected with a pool of four siRNAs targeting
ADAM12 or a pool of control siRNAs. b Hs578T cells were transfected
with a pool of four siRNAs targeting ADAM12 or with a pool of control
siRNAs. c SUM159PT cells were transfected with individual siRNAs, as
indicated. Cell surface expression of ADAM12 was evaluated by flow
cytometry. (TIF 556 kb)
Additional file 8: Figure S7. Inducible ADAM12 knockdown in
SUM159PT cells increases cell surface expression of CD24.
SUM159PT_shADAM12 (a) or SUM159_shControl cells (b) were incubated
for 4 days with or without 1 μg/ml of doxycycline. Cell surface expression
was evaluated by flow cytometry. Percentages of CD24+ cells stained
with FITC-conjugated anti-CD24 antibody, but not with isotype control
antibody, are indicated. (TIF 706 kb)
Additional file 9: Figure S8. Canonical pathways identified by IPA
based on differentially expressed genes in response to ADAM12
knockdown. P-values for the canonical pathways are calculated by
Fisher's exact test, right-tailed. The orange and blue colored bars
indicate predicted pathway activation, or predicted inhibition, respectively
(z-score). (TIF 572 kb)
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